Water Street Healthcare Partners has invested in Orgentec Diagnostika, a specialty diagnostics company. Water Street has committed equity to both acquire a majority position in Orgentec and invest in future acquisitions.
Orgentec specializes in diagnostic assays for autoimmune and infectious diseases. It offers a portfolio of more than 300 tests, primarily enzyme-linked immunosorbent assays (ELISA), that help diagnose rheumatology, thrombosis and gastroenterology disorders, as well as infectious diseases. It also offers an automated instrument and associated test kits that enable laboratories to complete multiple assays and deliver faster results than traditional ELISA tests. The company was founded in 1988 and is headquartered in Mainz, Germany (www.orgentec.com).
The investment in Orgentec expands Water Street’s presence in the specialty diagnostics sector, particularly in Europe and emerging markets. Scott Garrett, former chairman and CEO of Beckman Coulter and senior operating partner with Water Street, will serve as chairman of Orgentec.
“I’m excited to partner with Water Street to expand Orgentec into new areas of testing and increase our presence in emerging markets. Water Street has incredibly deep knowledge and extensive relationships in our industry,” said Dr. Wigbert Berg, who co-founded Orgentec in 1988. “Its team has worked closely with us to create a plan that supports our goal of thoughtfully growing Orgentec into a global leader that will bring greater value to our customers and employees.”
Dr. Berg will maintain an ownership position in Orgentec and serve on the company’s board of directors. He and Water Street have appointed Werner Hofacher, an executive with more than 30 years of experience in the diagnostics industry, to serve as CEO. Mr. Hofacher most recently led European operations for Beckman Coulter, and previously held leadership positions at Baxter and Dade Behring.
“It is an honor to be selected by Water Street and Dr. Berg to build on Orgentec’s history of success. For more than 25 years, the company has led the industry in developing new tests for complex diseases that were previously difficult to diagnose,” said Mr. Hofacher. “With Water Street’s support, we have a unique opportunity to expand Orgentec’s global position and to grow its portfolio of tests in order to help providers detect rare conditions and positively impact millions of lives.”
Water Street Healthcare Partners targets investments ranging from $50 million to $500 million in four health care sectors: distribution, medical products, health care services, and pharmaceutical products and services. The firm has particular expertise in corporate divestitures from healthcare companies. Water Street has more than $1 billion of capital under management and is based in Chicago (www.waterstreet.com).
Orgentec is Water Street’s third investment in a European-based business and its second new transaction announced in the past six weeks. Last month, Water Street signed agreements to acquire and merge CHS Health Services and Take Care Employer Solutions, a subsidiary of Walgreens.
© 2014 PEPD • Private Equity’s Leading News Magazine • 5-15-14